Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DDI study of HDM1002 in overweight/obese subjects
NCT07331389Phase 1Recruiting
- Sponsor
- Huadong Medicine
- Start
- Sep 2025
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of conveglipron in obesity, sponsored by Huadong Medicine. Primary endpoints: Area Under the Curve from time zero to infinity at 11 weeks, Maximum Observed Plasma Concentration at 11 weeks and 1 more. Started Sep 2025; status: recruiting.
02
Drugs
conveglipron
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07331389.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07331389.